Myriad Genetics Inc (MYGN)

MYGN (NASDAQ:Diversified Services) EQUITY
$29.58
pos +0.46
+1.58%
Today's Range: 29.37 - 30.01 | MYGN Avg Daily Volume: 905,100
Last Update: 06/28/16 - 3:59 PM EDT
Volume: 917,174
YTD Performance: -32.53%
Open: $30.01
Previous Close: $29.12
52 Week Range: $30.30 - $46.24
Oustanding Shares: 70,298,970
Market Cap: 2,108,969,100
6-Month Chart
TheStreet Ratings Grade for MYGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 5 5
Moderate Buy 0 0 0 0
Hold 6 6 5 5
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.38 2.38 2.44 2.44
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 20.27
Price Earnings Comparisons:
MYGN Sector Avg. S&P 500
20.27 20.30 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-19.89% -14.70% 9.72%
GROWTH 12 Mo 3 Yr CAGR
Revenue -7.10 0.50 0.13
Net Income -54.50 -0.30 -0.10
EPS -52.20 -0.20 -0.06
Earnings for MYGN:
EBITDA 0.16B
Revenue 0.72B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (06/16) FY (06/17)
Average Estimate $0.38 $0.43 $1.65 $1.78
Number of Analysts 9 7 11 11
High Estimate $0.39 $0.45 $1.66 $1.90
Low Estimate $0.36 $0.41 $1.63 $1.56
Prior Year $0.41 $0.41 $1.45 $1.65
Growth Rate (Year over Year) -8.13% 4.88% 13.67% 8.00%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Timothy Collins

 | Aug 31, 2015 | 10:37 AM EDT

The stock still maintains a bullish slant on the daily chart.

bullishMyriad upgraded at Wells

Aug 25, 2015 | 7:11 AM EDT

MYGN was upgraded from Market Perform to Outperform, Wells Fargo said. Recent meeting with management confirms a better business outlook. 

bearishMyriad downgraded at Credit Suisse

Feb 4, 2015 | 7:51 AM EST

MYGN was downgraded from Neutral to Underperform, Credit Suisse said. $30 price target. Estimates also cut, given the company's new guidance. 

bullishMyriad upgraded at JMP

Feb 4, 2015 | 7:40 AM EST

MYGN was upgraded from Market Perform to Outperform, JMP Securities said. $50 price target. Stock is attractive, following a 15% decline. 

By

Robert Moreno

 | Oct 2, 2014 | 2:17 PM EDT

Charting setups in Myriad Genetics, Clovis Oncology and Aegerion Pharma.

bullishMyriad Genetics price target bumped at Jefferies

Apr 2, 2014 | 8:16 AM EDT

MYGN raised its number, Jefferies said. Driven by unexpected boost to BRCA pricing. $33 price target. 

bullishMyriad Genetics upgraded at Credit Suisse

Feb 7, 2014 | 8:25 AM EST

MYGN was upgraded from Underperform to Neutral, Credit Suisse said. $29 price target. Base business can hold up better than expected and the Crescendo purchase should add to growth. 

bullishMyriad Genetics upgraded at JMP

Feb 5, 2014 | 7:58 AM EST

MYGN was upgraded from Underperform to Market Perform, JMP Securities said. Company is executing well, despite increased competition. 

bearishMyriad Genetics downgraded at JMP

Dec 30, 2013 | 7:41 AM EST

MYGN was downgraded from Market Perform to Underperform, JMP Securities said. $15 price target. BRCA pricing is lower than expected. 

bearishMyriad Genetics downgraded at JMP

Dec 3, 2013 | 8:16 AM EST

MYGN was downgraded from Outperform to Market Perform, JMP Securities said. Company could face lower reimbursement levels.

First I want to share my daily chart that was already posted on twitter.  Note that the r...
Nike's (NKE) drop after reporting earnings, around 4:15 PM, should not have surprised RMP ...
Only a climb in the Emini S&P 500 that pushes up through 2065 on a sustained basis wil...

And I am usually an optimist by nature.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.